1-855-378-42281-855-378-4228
One of the out-patient treatment alternatives for individuals in Brookside battling with opioid dependence and addiction is called opioid maintenance therapy. Licensed centers and doctors are authorized to administer certain medications to opioid dependent clients, many of which are opioids themselves and are addictive. In low enough doses however, the client does not experience high feelings and also doesn't have severe cravings and is not in opioid withdrawal. Methadone is the first drug used for this reason, but there are other choices currently to pick from.
Methadone is an opioid and can be taken at an outpatient medical center licensed to dispense the med, that is taken on a daily basis in liquid or pill form. The price of the med is approximately one hundred and fifty dolloars a month. Buprenorphine is also an opioid based med, and is in pill form often taken every other day. But unlike Methadone that can only be given in well-regulated medical centers, Buprenorphine can be prescribed and administered in doctor's offices. The cost monthly of buprenorphine is about three hundred dollars a month for the generic version of the med. There is also a version of buprenorphine that contains the ingredient naloxone, that is a med that blocks the effects of opiates. A person consuming this formulation, AKA Suboxone, would find it more difficult to get high from opioids if they relapsed while taking the drug. It is also taken daily, and is priced approximately $450 a month. Naltrexone is an additional drug taken in opioid maintenance therapy, but unlike the other drugs aforementioned it is an opiate blocker and is not an opioid. A person has the choice to take this drug as a monthly shot, and that is called Vivitrol. As an opioid blocker, the drug prevents someone from experience being high from opioids, and in turn lowers the risk associated with relapse. This daily injection costs anywhere from $1000 to $1200 per month.
For All Drug and Alcohol Treatment Centers In Brookside, Click Here.
